



#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Hardin et al.
SERIAL NO.: 10/007,621
FILED: 12/03/01

§ ART UNIT NO.: 1645
§ EXAMINER: UNKNOWN
§ DOCKET NO.: 00007/02UTL
§
§
§
§
§

TITLE: Enzymatic Nucleic Acid Synthesis:
Compositions and Methods for Altering
Monomer Incorporation Fidelity

EV 123 140 732 US	CERTIFICATE OF MAIL BY EXPRESS MAIL	15 September 2002
Express Mail Number		Date of Deposit
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the:		
Post Office to Addressee		
Assistant Commissioner of Patent		15 September 2002
BOX SEQUENCE		Date of Signature
Robert W. Strozier		
Washington, D.C. 20231		

STATEMENT REGARDING SUBSTITUTE PAPER COPY OF SEQUENCE LISTING AND CRF COPY OF SEQUENCE LISTING

Dear Sir/Madam:

In response to a Notice to Comply with Sequence Rules, Applicant used the PatentIn 3.1 software for the United States Patent and Trademark Office to generate a hard copy and electronic copy of the sequence listing as required by the Notice.


Applicants' Attorney verifies that the paper and electronic listing are identical, both generated by PatentIn 3.1.

Applicants' Attorney has attempted in good faith to respond to this notice; however, Applicants' Attorney must point out that at numerous part of the specification, reference is made to specific enzymes and DNA molecules, without the actual sequence. Applicants did not include actual sequences because the actual sequences are not germane to this application. The application relates to functionalized dNTPs or other small molecules that increase base incorporation fidelity. The invention is not related to any specific nucleic acid sequence or peptide sequence.

If this submission is considered deficient, please have someone from the sequence compliance group call me. I have attempted several times to get an answer on the issue of whether a nucleic acid or peptide sequence listing is required for a mere reference to a specific nucleic acid molecule or a specific enzyme or polypeptide, without sequence listing, in an application.

Applicant's attorney has corrected a defect in the earlier submission: Sequence No. 2 was a repeat of Sequence No. 1 in the earlier submission and has been corrected in this submission to be identical to the sequence set forth on Page 59 of the Specification. The mistake was unintended and merely left out one primer sequence and duplicated another.

Respectfully submitted,



Date: **23 October 2002**

Robert W. Strozier, Reg. No. 34,024
Attorney for Applicants